Disc Medicine price target raised to $108 from $89 at Raymond James

Raymond James raised the firm’s price target on Disc Medicine (IRON) to $108 from $89 and keeps a Strong Buy rating on the shares. The announcement that bitopertin is among the first cohort of drugs to receive the FDA Commissioner’s National Priority Voucher is highly positive, potentially accelerating the bitopertin launch in EPP by more than a quarter, and further increasing the firm’s confidence in the prospects for accelerated approval, the analyst tells investors in a research note.